Every time Matthias is kicked out of a school or day camp for defying adults and clashing with other children, his mother, Joelle Kendle, inches closer to a decision she dreads. With each morning of arm-twisting and leg-flailing as she tries to get him dressed and out the door for first grade, the temptation intensifies.
Kendle is torn over whether to have Matthias, just 6 and already taking the stimulant Adderall for attention deficit hyperactivity disorder, go on a second and more potent medication: the antipsychotic Risperdal.
Her dilemma is shared by a steadily rising number of American families who are using multiple psychotropic drugs – stimulants, antipsychotics, antidepressants and others – to temper their children’s troublesome behavior, even though many doctors who mix such medications acknowledge that little is known about the overall benefits and risks for children.
In 2012 about one in 54 youngsters ages 6 through 17 covered by private insurance was taking at least two psychotropic medications – a rise of 44 percent in four years, according to Express Scripts, which processes prescriptions for 85 million Americans. Academic studies of children covered by Medicaid have also found higher rates and growth. Combined, the data suggest that about 1 million children are taking various combinations of psychotropics.
Risks of antipsychotics alone, for example, are known to include substantial weight gain and diabetes. Stimulants can cause appetite suppression, insomnia and, far more infrequently, hallucinations. Some combinations of medication classes, like antipsychotics and antidepressants, have shown improved benefits (for psychotic depression) but also heightened risks (for heart rhythm disturbances).
But this knowledge has derived substantially from studies in adults – children are rarely studied because of concerns about safety and ethics – leaving many experts worried that the use of multiple psychotropics in youngsters has not been explored fully.
There is also debate over whether the U.S. Food and Drug Administration’s database of patients’ adverse drug reactions reliably monitors the hazards of psychotropic drug combinations, primarily because only a small fraction of cases are ever reported. Some clinicians are left somewhat queasy about relying mostly on anecdotal reports of benefit and harm.
“When I prescribe multiple psychotropics, there’s a good reason – even if I don’t know the exact interactions or efficacy, there’s a clinical reason to give it a shot,” said Dr. J. Wesley Boyd, a psychiatrist at the Cambridge Health Alliance in Massachusetts. “But saying, ‘The last time I gave x, y and z to someone they did fine,’ that’s not science.”
Added Dr. David Rubin, a pediatrician at the Children’s Hospital of Philadelphia, “We don’t perform trials over the course of 10 years to see what our decisions now mean for later.”
This uncertainty further polarizes debate among those who denounce overmedication of children and those who want suffering youngsters to receive potentially helpful treatments. Parents like Kendle, 26, get caught in the middle, having to decide what is best for a child, navigating societal and medical pressures.
“I want to know more about what it means for him to be on two medications, and no one can really tell me,” said Kendle, a single mother in Concord.
Matthias can be wonderfully loving. But without warning, he can explode into fits of anger and despair. His mother has tried several behavior modification strategies and parenting techniques to only modest effect.
Last month, as the idea of Matthias going on Risperdal became more realistic every day, Kendle found little reassurance. The doctor offering the additional medication cautioned her: “We’re really feeling around in the dark with this stuff.”
Matthias’ summer had deteriorated quickly. On his first day of science camp in June, Kendle received several phone calls about his refusing to join activities, not eating his lunch and bolting from adults trying to corral him. In early July the camp said he was not welcome back.
This was alarmingly regular for a boy with little regularity in his life. Kendle had him when she was 20, married his father four months later, and was divorced about six months after that. (The father has no contact with Matthias.) Increasingly aggressive and uncontrollable, Matthias was dismissed from three preschool programs before he turned 5, which led to his taking medication for ADHD. Their home became even more chaotic when Kendle’s sister’s family needed to move in.
Last year, Kendle took Matthias to a local behavioral pediatrician, Dr. Lawrence Diller, and asked him to monitor her son as kindergarten brought greater demands. His triggers are both unpredictable and inexplicable: Water from a faucet turning hot too slowly, or his mother parking in the wrong spot, can send him into fits from which he does not recover for the rest of the day.
Often filling his worksheets with scribbles of frowning faces, Matthias barely made it through kindergarten. The doctor floated an option: adding Risperdal, which has shown promise in tempering disruptive behavior in some children.
“For Matthias, who might feel at times overwhelmed or anxious, he'll probably experience that less,” Diller explained to her. “But also more importantly the level of distress and the level of his anger will be decreased by the drug.”
Kendle asked, “Do you know the long-term effects?”
Diller explained Risperdal’s links to weight gain and diabetes, its unclear long-term effects on developing brains, and that its interactions with stimulants like Adderall had barely been studied. He acknowledged that he had never prescribed both medications to a child so young and cautioned against any quick diagnoses or decisions.
Keeping Matthias on Adderall was a relatively easy choice – its risks have been established over decades of use. But adding Risperdal would change the equation markedly.
Risperdal, known as risperidone in its generic form, is approved by the FDA as treatment only for autistic children younger than 10. Its expanding off-label use in young children like Matthias has been quite controversial, partly because most studies identifying behavioral improvement were underwritten by pharmaceutical companies, including Janssen, Risperdal’s manufacturer. Current American Academy of Child & Adolescent Psychiatry guidelines on antipsychotics state: “Much is still not known about the efficacy, tolerability, and long-term safety of these drugs in young people.”
Combining an antipsychotic with another psychotropic medication might help an individual child, the guidelines say, but the practice “has not been studied rigorously” and “should be avoided if possible.”
Many mental health providers, however, have decided that struggling children and families cannot wait for FDA approval.
Some physicians, meanwhile, counter that short-term relief provided by medication can obscure a child’s underlying psychological and environmental problems and prevent them from being closely examined.
A study published in the September journal of the academy for child psychiatry made one of the first formal attempts to evaluate the short-term addition of Risperdal to stimulants for children like Matthias, who have ADHD and are severely aggressive. The results after six weeks were mixed: Modest benefits were found in behavior at home but not at school, and there were slightly worse side effects, like weight gain, giving little guidance to clinicians.
It also gave little reassurance to parents like Kendle.
Kendle has heard stories, some from parents in her own community, of children similar to Matthias whose school lives were turned around by the relief that Risperdal can bring. Then she saw a television commercial in which class-action lawyers asked parents if their son had developed breasts while on the drug, a rare but disturbing side effect.
“Could we try it for a month, and then if you don’t see anything bad?” she asked Diller in his office in late October, her voice trailing off.
“The decision to try it,” Diller said, “doesn’t at all rule out stopping it.”
Still leery, Kendle decided to wait. Next week, she will meet with school officials about an Individual Education Plan, which could provide Matthias with more robust assistance – from more one-on-one attention from teachers to full special-education services.